Welcome to our dedicated page for Erasca news (Ticker: ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca stock.
Erasca, Inc. (NASDAQ: ERAS) is a clinical-stage precision oncology company that reports frequent updates related to its efforts to develop therapies for RAS/MAPK pathway-driven cancers. News about Erasca often centers on progress within its RAS-targeting franchise, including clinical, preclinical, regulatory, and intellectual property developments.
Investors following ERAS news can expect detailed announcements on the advancement of the company’s key product candidates, ERAS-0015 and ERAS-4001. Erasca issues releases on milestones such as investigational new drug (IND) clearances, initiation and progress of Phase 1 trials, and early clinical observations in patients with RAS-mutant and KRAS-mutant solid tumors. The company also reports on patent issuances that extend composition of matter protection for its molecules and on scientific presentations at major oncology and healthcare conferences.
Erasca’s news flow includes quarterly business updates and financial results, typically accompanied by commentary from management on the status of the AURORAS-1 and BOREALIS-1 trials, cash resources, and research and development priorities. The company additionally announces participation in investor conferences hosted by firms such as J.P. Morgan, Evercore, Guggenheim, Stifel, Jefferies, Goldman Sachs, and Morgan Stanley, where its leadership discusses strategy and pipeline progress.
For readers tracking ERAS, this news stream provides insight into how Erasca is advancing its clinical-stage programs targeting RAS and KRAS, how it is building its intellectual property position, and how management frames the opportunities and risks associated with its focus on RAS/MAPK pathway-driven cancers.
Erasca (Nasdaq: ERAS) priced an upsized public offering of 22,500,000 shares of common stock at $10.00 per share, generating expected gross proceeds of $225.0 million. The company granted the underwriters a 30‑day option to purchase up to an additional 3,375,000 shares at the offering price, less underwriting discounts and commissions.
The offering is expected to close on January 23, 2026, subject to customary closing conditions. Net proceeds, together with existing cash and securities, are intended to fund research and development of product candidates, other development programs, and for working capital and general corporate purposes.
Erasca (Nasdaq: ERAS) announced a proposed underwritten public offering of $150.0 million of common stock with a 30-day underwriter option to purchase up to an additional $22.5 million of shares. The company said it will use net proceeds together with existing cash and marketable securities to fund research and development of product candidates, other development programs, and for working capital and general corporate purposes. The offering will be made under a shelf registration statement declared effective on August 22, 2025, and a preliminary prospectus supplement will be filed with the SEC. There is no assurance the offering will be completed or as to final size or terms.
Erasca (NASDAQ: ERAS) reported early Phase 1 clinical progress for its RAS franchise. ERAS-0015 showed ongoing responses including two confirmed partial responses and one unconfirmed partial response observed at 8 mg QD, with favorable safety (no dose-limiting toxicities) and linear pharmacokinetics; data cutoff was January 7, 2026. INDs for ERAS-0015 and ERAS-4001 were cleared in May 2025. Initial Phase 1 monotherapy topline data for ERAS-0015 are planned for H1 2026, with expansion and combination cohorts in H2 2026 and additional data in 2027. ERAS-4001 monotherapy topline data are planned for H2 2026 with cohorts in 2027.
Erasca (Nasdaq: ERAS) announced it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
Management will present on Tuesday, January 13, 2026 at 1:30 PM PT, participate in one-on-one investor meetings, and provide a live audio webcast at Erasca.com/events. An archived replay will be available for 30 days after the webcast.
Erasca (Nasdaq: ERAS) will present at the 8th Annual Evercore Healthcare Conference in Coral Gables, FL.
Management will take part in a fireside chat on Wednesday, December 3, 2025 at 10:25 AM ET, hold one-on-one investor meetings, and provide a live audio webcast at Erasca.com/events. An archived replay will be available for 30 days after the webcast.
Erasca (Nasdaq: ERAS) reported third quarter 2025 business updates and financial results on Nov 12, 2025. Key items: a U.S. composition-of-matter patent (No. 12,458,647) was issued for the pan-RAS molecular glue ERAS-0015 covering compositions until September 2043; initial Phase 1 monotherapy data for ERAS-0015 and the pan-KRAS inhibitor ERAS-4001 are expected in 2026; and Robert Shoemaker, Ph.D., was promoted to chief scientific officer.
Financials: cash, cash equivalents, and marketable securities were $362.4M as of Sept 30, 2025 (down from $440.5M at Dec 31, 2024) and are expected to fund operations into H2 2028. Q3 R&D expense was $22.5M; G&A was $10.1M; net loss was $30.6M or $(0.11) per share.
Erasca (Nasdaq: ERAS) announced that the U.S. Patent and Trademark Office issued Patent No. 12,458,647, titled “Macrocyclic Derivative And Use Thereof,” covering the composition of matter for the pan‑RAS molecular glue ERAS-0015 and related compositions.
The patent provides protection through September 2043, subject to possible patent term adjustments or extensions. The company noted it in‑licensed the program in May 2024 and said initial Phase 1 monotherapy data for ERAS-0015 and for pan‑KRAS inhibitor ERAS-4001 are expected in 2026.
Erasca (Nasdaq: ERAS) announced management will participate in investor conferences and one-on-one meetings in November 2025. Events and times:
- Guggenheim 2nd Annual Healthcare Innovation Conference — Boston, Nov 10-12; Fireside chat on Nov 11 at 2:00 pm ET.
- Stifel 2025 Healthcare Conference — New York, Nov 11-13; Fireside chat on Nov 12 at 1:20 pm ET.
- Jefferies Global Healthcare Conference — London, Nov 17-20; Fireside chat on Nov 19 at 10:30 am GMT.
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancer therapies, will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company's management will deliver a presentation on Tuesday, September 9, 2025, at 3:20 PM ET at the Sheraton New York Times Square and engage in one-on-one investor meetings.
Investors can access a live audio webcast of the presentation through Erasca.com/events, with a replay available for 30 days following the event.
Erasca (Nasdaq: ERAS), a precision oncology company, reported significant progress in its RAS-targeting cancer therapy development program and Q2 2025 financial results. The company achieved key milestones with FDA clearance for two investigational new drug (IND) applications: ERAS-4001 (pan-KRAS inhibitor) and ERAS-0015 (pan-RAS molecular glue), both targeting RAS-mutant solid tumors.
The company maintains a strong financial position with $386.7 million in cash and equivalents as of June 30, 2025, expected to fund operations into H2 2028. Q2 2025 saw reduced losses with a net loss of $33.9 million ($0.12 per share), compared to $63.2 million ($0.29 per share) in Q2 2024. Initial Phase 1 monotherapy data for both drug candidates is expected in 2026.
FAQ
What is the current stock price of Erasca (ERAS)?
What is the market cap of Erasca (ERAS)?
